Tags : Ocular Disease Pipeline

M&A

SparingVision Acquires GAMUT Therapeutics to Expands its Novel Ocular Disease

Shots: The acquisition expands SparingVision’s ocular genomic medicine pipeline with the addition of GAMUT’s lead product SPVN20, which is a novel, mutation-agnostic gene therapy, focuses on restoring the function of dormant cone cells in the retina. The acquisition is expected to close in Q2’21 SparingVision plans to evaluate the therapeutic synergy with a combination of […]Read More